YXYitong Xu

Yitong Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yitong Xu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Death pathway plasticity in therapy resistance: mechanistic switches and translational opportunities

    by Jingqian Guan, Kexin Liang, Hongjiu Ren, Yitong Xu, Hongbo Su, Xizi Jiang

    Regulated cell death (RCD) programs in cancer have traditionally been framed as discrete pathways defined by signature effectors, including caspases (apoptosis), RIPK1–RIPK3–MLKL (necroptosis), gasdermins (pyroptosis), lipid peroxidation control nodes (ferroptosis), PARP1–AIF/MIF (parthanatos), and FDX1-dependent lipoylation stress (cuproptosis). Here, we advance an integrated view in which these programs function as a configurable decision network rather than isolated routes. Therapeutic and microenvironmental inputs, such as death ligands, chemoradiotherapy, targeted agents, PARP inhibition, copper ionophores, nutrient/oxidative stress, extracellular matrix detachment, and cytotoxic T-cell pressure, converge on shared hub modules that act as rheostats, routing cells toward distinct execution outcomes or into drug-tolerant persister states. This circuit-level framing explains context-dependent switching and mixed phenotypes, including caspase-8/c-FLIP control of apoptosis–necroptosis, caspase–gasdermin coupling of apoptosis–pyroptosis, and metabolic–redox tuning of ferroptosis susceptibility via SLC7A11–GPX4–ACSL4–FSP1 and autophagy-linked lipid/iron handling. We outline a biomarker and functional assay framework to map tumor death wiring from biopsies and organoid challenges, enabling rational combination strategies that exploit death program plasticity while anticipating resistance and inflammatory toxicities.

  • Open Access

    Case Report: Diagnosis and management of primary malignant melanoma of the bladder: a case-based review

    by Xiaolong Hou, Xiaoxiao Xu, Yongxu Chen, Bohao Jiang, Yitong Xu, Hao Zhang

    Background: Primary malignant melanoma of the bladder (PMMB) represents an extraordinarily rare diagnostic entity among bladder malignancies, with fewer than 50 well-documented cases reported in modern medical literature. Due to its rarity, standardized treatment protocols remain undefined, and prognostic outcomes are poorly characterized. Case presentation: A 65-year-old man presented with a primary complaint of urinary tract irritation symptoms and an occupying lesion on the bladder wall detected during an enhanced CT scan. He underwent partial cystectomy and left ureterovesical reimplantation, and pathological results confirmed the diagnosis of PMMB. The prognosis was favorable, with no recurrence observed during a 24-month follow-up. Additionally, a comprehensive literature review was conducted to elucidate the typical characteristics and current therapeutic approaches reported to date, as evidence-based guidelines have yet to be established. Conclusion: Although PMMB is a rare bladder malignancy, certain similarities in its clinical and imaging features have been observed among the reported series. This study provides an additional summary of the tumor’s biological characteristics while discussing current treatment paradigms, future perspectives, and potential therapeutic strategies.

  • Open Access

    Two rare cases of primary clear cell adenocarcinoma of the urethra: clinical experience, case report and literature review

    by Bohao Jiang, Jiyuan Hu, Benqiao Wang, Xujia Liu, Ling Tong, Yitong Xu, Hao Zhang

    Background: Primary clear cell adenocarcinoma of the urethra (CCAU) is a kind of extremely rare genitourinary cancer. Despite the similarity in the clinical manifestations of these reported cases, diagnosis and determination of standard therapy remain challenging due to the rarity of findings and similarity with other urethral tumors.Case presentation: Herein, we reported two cases of CCAU with the same chief complaint of hematuria: a 71-year-old female and a 66-year-old male. The male patient reported concomitant symptoms of frequent and painful urination. CT scans show abnormal enhancements. After a cystoscopy examination, both patients are diagnosed with malignant urethral tumors. Surgical resections and additional pathological examinations support the diagnosis of CCAU (palliative resection for case 1 and transurethral resection for case 2). Case 1 undergone progression 6 months after initial treatment with transurethral resection and chemotherapy with a 15-month overall survival. In contrast, the prognosis of case 2 remained uneventful 10 months after surgery without recurrence. After presenting our cases, we launched a literature review that included 23 articles and 33 cases of CCAU to summarize the characteristics of the disease.Conclusion: Primary clear cell adenocarcinoma of the urethra is a rare malignant urethral tumor with controversial histological origins. Primary symptoms include hematuria and changes in voiding habits. Middle-aged and elderly females are more susceptible to primary clear-cell adenocarcinoma of the urethra. Unfortunately, it is difficult to differentiate primary clear-cell adenocarcinoma of the urethra from other urethral tumors due to similar clinical features. However, imaging tools such as CT, MRI, and cystoscopy are adjunctive in confirming diagnoses. Even though surgical resection is the primary treatment to relieve clinical symptoms, prevent recurrence, and confirm diagnosis, no standard surgical protocol is available. The therapeutic effect of postoperative adjuvant therapies remains unclear. Future investigations on CCAU are necessary to advance clinical knowledge and to provide treatment guidance.


  • Open Access

    Retroperitoneal bronchogenic cyst: a case report and literature review

    by Bohao Jiang, Tiantian Xie, Jiyuan Hu, Yitong Xu, Hao Zhang

    Introduction: Retroperitoneal bronchogenic cyst, typically situated in the subdiaphragmatic region, is a rare congenital benign developmental abnormality arising from dysplasia of the foregut and abnormal budding of the tracheobronchial tree. Due to its low incidence, there are limited reports regarding this condition.Case presentation: Four retroperitoneal bronchogenic cysts near the left adrenal gland were identified without accompanying clinical symptoms. One case was misdiagnosed as an adrenal tumor prior to surgery, while the others were diagnosed as retroperitoneal cysts of uncertain origin. All cases underwent surgical resection, with three being performed laparoscopically and one utilizing robot-assisted techniques. Pathological reports confirmed the diagnosis of bronchogenic cyst in each instance. The prognosis was favorable for all four patients, with no complications or recurrences observed. Additionally, a literature review was conducted, encompassing 82 cases, which revealed similar characteristics and radiological manifestations in the majority of cases.Conclusion: Although retroperitoneal bronchogenic cysts are rare developmental malformations lacking distinctive clinical and radiological features, reported cases exhibit similarities in certain clinical and imaging characteristics. This report offers additional insights into the diagnosis and management of this rare disease. Future reports are essential to enhance understanding of this disease.


  • Open Access

    Tetraspanin 3 promotes NSCLC cell proliferation via regulation of β1 integrin intracellular recycling

    by Yao Zhang, Chenglong Wang, Yitong Xu, Hongbo Su

    Background: The involvement of tetraspanins in cancer development has been widely implicated. In this study, the function and molecular mechanisms of tetraspanin 3 (TSPAN3) in non-small cell lung cancer (NSCLC) cells were explored. Methods: Tissue samples from patients diagnosed with NSCLC were analyzed by immunohistochemistry, western blotting, and real-time polymerase chain reaction (PCR) to indicate the involvement of TSPAN3 in cancer progression. In the meantime, we also performed exhaustive mechanistic studies using A549 and H460 cells in vitro through a variety of methods including western blotting, real-time PCR, immunofluorescent staining, coimmunoprecipitation, cell proliferation assay, and nocodazole (NZ) washout assay. Proper statistical analysis was implemented wherever necessary in this study. Results: TSPAN3 was found to be highly expressed in lung cancer cells and tissues. Moreover, high levels of TSPAN3 positively correlated with poor differentiation, lymph node involvement, advanced pathological tumor-node-metastasis stage, and poor prognosis in patients with NSCLC. TSPAN3 showed potential to promote the proliferation of NSCLC cells in vitro and in vivo. Specifically, TSPAN3 was found to interact with β1 integrin via the LEL domain, thereby facilitating the sorting of β1 integrin into Rab11a endosomes and promoting β1 integrin recycling and upregulation. Conclusions: Our findings reveal TSPAN3 may represent a potentially valuable therapeutic target for NSCLC.